Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7856)	11/27/1998 5:08:00 PM
From: Tharos	Respond to of 17367

Can one say that the press release could of just said for tax reasons and future collaborations and left out anticipation of possible approval of Neuprex? Would it seem that Xoma would put in the press release in anticipation of Neuprex approval to influence your vote or was it done just to publicize their anticipation? And once said move is approved by shareholders, will the US Treasury Dept still be able to collect enough revenues to keep the White House stocked with cigars?

To: Bluegreen who wrote (7856)	11/27/1998 6:10:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Remember PERT and Critical Path? Was, IMO, sort of a fad but there is a certain inescapable logic to planning ahead and starting certain things before others. Are you saying XOMA should wait until Neuprex is approved before beginning the process to attempt to change domicile? Are you sure the tax consequences are the same for revenue yet to be generated as for existing revenue? In addition if one does not anticipate revenue there is no real rational for a change in domicile. When do you think we will receive the prospectus? When do you think the vote will be taken? I think we will be into Jan. by the time this happens and we may have seen something of the DSMB final review by then, Don't know but it is something to anticipate.